- POSITIVE
Annual Revenue Infinium Pharmachem Mar-2026 Annual Revenue is Rs 158 Cr which is growth of 13.5% YoY.
- POSITIVE
Annual Net Profit Infinium Pharmachem Mar-2026 Annual Net Profit is Rs 10 Cr which is growth of 18.3% YoY.
NSE: INFINIUM
Infinium Pharmachem Live Share Price Today, Share Analysis and Chart
aboutInfinium Pharmachem Ltd. (INFINIUM) is a specialized chemical company focused on the manufacturing and supply of iodine-based compounds. The company operates as a key player in the niche iodine chemistry market, catering to a diverse range of industr... Read More
281.003.00(1.08%)
2,500
NSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Infinium Pharmachem Stock Price Analysis
Day Price Range1.1% 1 Day return | 281 (LTP) 281285.8 LowHigh |
|---|---|
Week Price Range-1.8% 1 Week return | 281 (LTP) 269299 LowHigh |
Month Price Range-3.6% 1 Month return | 281 (LTP) 269324.5 LowHigh |
52 Week Price Range6.0% 1 Year return | 281 (LTP) 189.4324.5 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Infinium Pharmachem annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|---|---|---|---|---|
15.4% | 23.4% | 157.9 | 139.1 | 124 | 102.7 | 75 | 55.2 | 36.6 | ||
Operating Exp. Ann. | 17.5% | 22.9% | 139.5 | 121.8 | 104.9 | 86.1 | 65.3 | 49.7 | 33.4 | |
Operating Profit Ann. | 3.8% | 28.2% | 17 | 15.2 | 17.4 | 15.2 | 8.7 | 4.9 | 2.6 | |
OPM Ann. % | -10.1% | 3.8% | 10.75% | 10.90% | 14.05% | 14.81% | 11.63% | 8.90% | 7.17% | |
16.9% | 22.9% | 144.3 | 127.4 | 109.1 | 90.4 | 67.6 | 51.4 | 35.2 | ||
EBITDA Ann. | 3.5% | 27.3% | 18.4 | 17.3 | 19 | 16.6 | 9.6 | 5.5 | 3.2 | |
EBITDA Ann. margin % | -10.3% | 3% | 11.64% | 12.43% | 15.36% | 16.12% | 12.87% | 10.03% | 8.74% | |
Interest Ann. | -8.5% | 15.9% | 2.3 | 2.7 | 1.8 | 3 | 1.7 | 1.1 | 1.2 | |
Depr. | 26% | 30% | 2.6 | 3 | 2.4 | 1.3 | 0.6 | 0.7 | 0.6 | |
PBT Ann. | 3.2% | 28.9% | 13.5 | 11.6 | 14.9 | 12.3 | 7.4 | 3.8 | 1.4 | |
Tax Ann. | 4.1% | 28.5% | 3.5 | 3.1 | 3.8 | 3.1 | 1.9 | 1 | 0.4 | |
2.8% | 29.9% | 10 | 8.5 | 11.1 | 9.2 | 5.5 | 2.7 | 1 | ||
Net Profit Ann. | 2.8% | 29.9% | 10 | 8.5 | 11.1 | 9.2 | 5.5 | 2.7 | 1 | |
NPM Ann. % | -10.8% | 5.1% | 6.40% | 6.18% | 9.06% | 9.03% | 7.43% | 4.98% | 2.82% | |
EPS Adj. latest Ann. | 2.9% | 29.2% | 7.2 | 6.1 | 8 | 6.6 | 4 | 2 | 0.7 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
13.5%
2Y CAGR
12.8%
3Y CAGR
15.4%
5Y CAGR
23.4%
Net Profit Ann.
1Y CHG
17.6%
2Y CAGR
-5.1%
3Y CAGR
2.8%
5Y CAGR
29.9%
Operating Exp. Ann.
1Y CHG
14.5%
2Y CAGR
15.3%
3Y CAGR
17.5%
5Y CAGR
22.9%
Infinium Pharmachem Technical Analysis
Infinium Pharmachem EMA & SMA
Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
| 5 Day | 282.0 |
|---|---|
| 10 Day | 286.9 |
| 12 Day | 288.0 |
| 20 Day | 288.9 |
| 26 Day | 287.2 |
|---|---|
| 50 Day | 275.5 |
| 100 Day | 256.7 |
| 200 Day | 244.6 |
Infinium Pharmachem Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 2026100.0%
Week91.2%
Month83.6%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Infinium Pharmachem Resistance and Support
282.58
Pivot
| First Resistance | 284.2 |
|---|---|
| Second Resistance | 287.3 |
| Third Resistance | 288.9 |
| First Support | 279.4 |
|---|---|
| Second Support | 277.8 |
| Third Support | 274.7 |
| Day RSI | 46.5 |
|---|---|
| Day MACD | 0.8 |
| Day MFI | 52.7 |
| Day MACD Signal Line | 5.5 |
Infinium Pharmachem Beta
| 1 Month | -0.8 |
|---|---|
| 1 Year | 0.0 |
| 3 Month | -0.5 |
|---|---|
| 3 Year | 0.1 |
Infinium Pharmachem Price Change Analysis
↓-3.6%
Over 1 Month
LowHigh
269324.5
↑34.8%
Over 3 Months
LowHigh
202324.5
↑29.9%
Over 6 Months
LowHigh
190324.5
↑6.0%
Over 1 Year
LowHigh
189.4324.5
Infinium Pharmachem Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 18 Apr 2023 | 146 | 50,000 | NSE |
| RUSHABH BHARATBHAI | Bulk | Sell | 18 Apr 2023 | 153.34 | 38,000 | NSE |
| SWASTIKA INVESTMART LIMITED | Bulk | Sell | 17 Apr 2023 | 148.55 | 30,000 | NSE |
| SHRIPAL V VORA (HUF) | Bulk | Purchase | 17 Apr 2023 | 148.45 | 36,000 | NSE |
| DHARAMSHI GORDHANBHAI PATEL | Bulk | Purchase | 17 Apr 2023 | 141.50 | 35,000 | NSE |
| PRAGNA HITESH LUNAGARIYA | Bulk | Purchase | 17 Apr 2023 | 141.50 | 76,000 | NSE |
| SWASTIKA INVESTMART LIMITED | Bulk | Purchase | 17 Apr 2023 | 141.50 | 50,000 | NSE |
| BHUPESH VAHALABHAI PATEL | Bulk | Purchase | 17 Apr 2023 | 141.50 | 45,000 | NSE |
| MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Purchase | 17 Apr 2023 | 141.50 | 50,000 | NSE |
Infinium Pharmachem Corporate Actions
Infinium Pharmachem Bonus shares
Infinium Pharmachem bonus history along with announcement, record, ex-bonus dates, and bonus ratios.
#Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
113 Sep 2023 | 1:1 | 13 Sep 2023 |
Infinium Pharmachem Board Meetings
Infinium Pharmachem past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
106 Nov 2026 | Quarterly Results | - |
222 Aug 2026 | Others | To consider other business matters |
329 May 2026 | Audited Results & Others | To consider other business matters. |
413 Mar 2026 | Others | To consider other business matters. |
513 Nov 2025 | Quarterly Results | - |
Infinium Pharmachem Documents
Infinium Pharmachem Credit Ratings
Infinium Pharmachem credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 20 Sep 2026 | icra ratings | INFINIUM PHARMACHEM LIMITED | [ICRA]BBB (Stable); Assigned | Link |
Infinium Pharmachem - Company Profile
Infinium Pharmachem Management Structure
Infinium Pharmachem management structure with salaries, total experience, and qualifications.
Infinium Pharmachem Board of Directors
Infinium Pharmachem Board of directors with salaries, total experience, and qualifications.
Website: infiniumpharmachem.com
About the company - Business Profile
Infinium Pharmachem Ltd. (INFINIUM) is a specialized chemical company focused on the manufacturing and supply of iodine-based compounds. The company operates as a key player in the niche iodine chemistry market, catering to a diverse range of industries including pharmaceuticals, agrochemicals, electronics, and specialty chemicals. It leverages its research and development capabilities to provide complex iodine derivatives and active pharmaceutical ingredients (APIs).
Key Points
- Key Facts:
- Incorporation: The company was incorporated in 2003.
- Headquarters: Ahmedabad, Gujarat.
- Stock Listing: Listed on the NSE SME platform (Emerge).
- Products: Over 200 iodine derivatives and pharmaceutical intermediates.
- Operations and Resources:
- The company operates a manufacturing facility in Sojitra, Gujarat, which is compliant with current Good Manufacturing Practices (cGMP).
- It maintains a dedicated R&D center focused on process optimization and the development of new molecules.
- The facility handles various complex chemistries such as iodination, oxidation, and reduction.
- Privatization and Ownership:
- Infinium Pharmachem is a promoter-led organization, with a significant majority stake held by the founding family and associated entities.
- Market and Significance:
- The company is a major supplier of iodine derivatives in India and exports to international markets including Europe, Asia, and North America.
- Its products are essential in medical imaging (contrast media), sanitizers, and chemical synthesis.
- Sustainability and Innovation:
- Current focus areas include Iodine Recovery and recycling processes to manage high raw material costs and environmental impact.
- The company aims to expand its API portfolio and enter more regulated global markets.
- Business Model:
- Infinium operates on a CRAMS (Contract Research and Manufacturing Services) and generic product supply model.
- It excels in handling hazardous and complex iodination reactions, maintaining a supply chain for iodine, which is a scarce resource.
- Revenue Breakdown:
- By Segment: Approximately 85-90% of revenue is derived from iodine-based derivatives and specialty chemicals, with the remainder from pharmaceutical intermediates and APIs.
- By Geography: Revenue is distributed between Domestic (approx. 60-65%) and Export (approx. 35-40%) markets.
- Key Products and Technology:
- Core Products: Potassium Iodate, Sodium Iodide, Methyl Iodide, and various Periodates.
- Advancements: Implementation of closed-loop manufacturing systems for iodine recovery and solvent recycling.
- Employee and Management:
- The company maintains a workforce of over 100 employees across manufacturing and administrative functions.
- Strategic Initiatives:
- Ongoing capacity expansion at the Sojitra plant to meet growing demand in the contrast media and pharmaceutical sectors.
- Strengthening raw material sourcing through long-term arrangements with iodine miners in Chile and Japan.